ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1046

Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology

Katherine Schoeffler, Stephanie Beveridge, Max Bouvette, Veera Durga Vaishnavi Kurra, Reema Moussa, Ryan Johnson, Camille Goerend, Nimrah Bader and Ryan Nipp, University of Oklahoma College of Medicine, Oklahoma City, OK

Meeting: ACR Convergence 2024

Keywords: Cost-Effectiveness, Economics, Health policy, Health Services Research, Medicare

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Health Services Research – ACR/ARP Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Recent policy changes and competitive alternative drug pricing models present the potential for medication cost savings. In this study, we sought to assess the cost differences between alternative drug sourcing models, such as Mark Cuban Cost Plus Drugs (MCCPD) and Costco Membership Prescription Company (CMPC), compared to Medicare Part D purchasing on medications frequently prescribed by rheumatologists.

Methods: We assessed the drug costs of 24 commonly prescribed rheumatologic medications across MCCPD, CMPC, and Medicare Part D provider drug claims. Medications within Table 1 were identified by Part D Provider and Drug rheumatology claim volume and simultaneous availability on MCCPD and CMPC as of January 2024. We included those in tablet or capsule form, excluding injectable medications due to the lack of exact dose units. When multiple dosage options were available for the same medication, we selected the dose most utilized in clinical practice. We extracted total spending, unit price, and units (tablets/capsules) dispensed from 2022 Medicare Part D Spending by Drug data. Total spending was adjusted to reflect changes in costs from 2022-2023 using Medicaid’s National Average Drug Acquisition Cost (NADAC) database. We extracted the cost-per-pill for each medication from Medicare Part D data and  compared this with the cost-per-pill for MCCPD and CMPC at both maximum (90-count) and minimum (30-count) supply volume.

Results: With MCCPD 30-count supply purchasing, 37.5% (n=9/24) of drugs showed a savings (net of $552 million, rounded to the nearest million) with an average savings of 43.6% when compared to Medicare spending on the same drugs. Purchasing through the MCCPD 90-count supply model resulted in savings of $1.09 billion across 18/24 drugs, with an average savings of 45.1%. In the CMPC 30-count supply model, there was a net savings of $418 million across 9/24 drugs, with an average savings of 35.4%. The CMPC 90-count supply model showed a net savings of $839 million across 16/24 drugs, with an average percent savings of 38.7%. Savings (+) or losses (-) for each individual drug are displayed in Table 2 and Table 3. Table 1 displays each drug ranked by claim volume and their respective drug category.

Conclusion: In this study, we demonstrated that medication purchasing through MCCPD and CMPC conferred significant potential savings on many common rheumatologic drugs when compared to Medicare Part D spending. Drugs in the 90-count, or maximum supply model, were generally more cost effective than in the 30-count model, though both categories demonstrated price points on particular drugs that were competitive with or exceeding that of Medicare. Alternative drug sourcing may play a role in both alleviating healthcare spending and navigating economic barriers to care. Awareness of specific drugs with cost-effective availability via these competitive models may assist in relieving patient and physician concerns about medication costs.

Supporting image 1

Rheumatology Drugs Ranked by Medicare Part D Provider & Drug Claim Volume (2021)

Supporting image 2

Potential Medicare Savings Using Mark Cuban Cost Plus Drugs Pricing

Supporting image 3

Potential Medicare Savings Using Costco Membership Prescription Company Pricing

Disclosures: K. Schoeffler: None; S. Beveridge: None; M. Bouvette: None; V. Kurra: None; R. Moussa: None; R. Johnson: None; C. Goerend: None; N. Bader: None; R. Nipp: None.

To cite this abstract in AMA style:

Schoeffler K, Beveridge S, Bouvette M, Kurra V, Moussa R, Johnson R, Goerend C, Bader N, Nipp R. Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/shifting-paradigms-in-drug-spending-a-study-of-medicare-part-d-versus-emerging-pharmacy-models-in-rheumatology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/shifting-paradigms-in-drug-spending-a-study-of-medicare-part-d-versus-emerging-pharmacy-models-in-rheumatology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology